[1]马 亮.连续性静脉-静脉血液滤过联合血液灌流治疗ICU脓毒症患者的效果观察[J].医学信息,2021,34(13):107-109.[doi:10.3969/j.issn.1006-1959.2021.13.027]
　MA Liang.Observation on the Effect of Continuous Venous-venous Hemofiltration Combined with Hemoperfusion in the Treatment of Patients with Sepsis in ICU[J].Medical Information,2021,34(13):107-109.[doi:10.3969/j.issn.1006-1959.2021.13.027]
点击复制

连续性静脉-静脉血液滤过联合血液灌流治疗ICU脓毒症患者的效果观察()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年13期
页码:
107-109
栏目:
论著
出版日期:
2021-07-01

文章信息/Info

Title:
Observation on the Effect of Continuous Venous-venous Hemofiltration Combined with Hemoperfusion in the Treatment of Patients with Sepsis in ICU
文章编号:
1006-1959（2021）13-0107-03
作者:
马 亮
（佳木斯市中心医院ICU，黑龙江 佳木斯 154002）
Author(s):
MA Liang
(ICU,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
脓毒症; 连续性静脉-静脉血液滤过; 血液灌流
Keywords:
Sepsis; Continuous venous-venous hemofiltration; Hemoperfusion
分类号:
R459.7
DOI:
10.3969/j.issn.1006-1959.2021.13.027
文献标志码:
A
摘要:
目的 观察连续性静脉-静脉血液滤过联合血液灌流治疗ICU脓毒症的效果。方法 选择2016年2月~2019年8月收治于我院ICU的87例脓毒症患者作为研究对象，将其随机分成对照组（43例）和观察组（44例），常规治疗的基础上给予对照组患者连续性静脉-静脉血液滤过治疗（CVVH），观察组在对照组基础上联合血液灌流治疗（CVVH+HP）。比较两组治疗前后实验室指标[白细胞计数（WBC）、血红蛋白（Hb）、尿素氮（BUN）、血肌酐（Scr）、血乳酸（LAC）、超敏C反应蛋白（hs-CRP）]、尿量、炎性因子水平[白介素-6（IL-6）、白介素-8（IL-8）、肿瘤坏死因子（TNF-α）]、ICU住院时间、总住院时间及死亡率。结果 治疗后两组WBC、Hb、BUN、Scr、LAC、hs-CRP均较治疗前降低，尿量较治疗前升高，所有指标均得到改善，且观察组改善优于对照组，差异有统计学意义（P＜0.05）；治疗后两组IL-6、IL-8及TNF-α炎性因子水平均低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）；观察组ICU住院时间、总住院时间及死亡率均低于对照组，差异有统计学意义（P＜0.05）。结论 在常规治疗的基础上，采用连续性静脉-静脉血液滤过联合血液灌流治疗ICU脓毒症，可有效改善患者的实验室指标及尿量、降低炎性因子水平、缩短住院时间，降低死亡率，值得临床应用。
Abstract:
Objective To observe the effect of continuous venous-venous hemofiltration combined with hemoperfusion in the treatment of sepsis in ICU.Methods 87 patients with sepsis admitted to the ICU of our hospital from February 2016 to August 2019 were selected as the research objects.They were randomly divided into a control group (43 cases) and an observation group (44 cases). On the basis of conventional treatment, patients in the control group were given continuous venous-venous hemofiltration (CVVH).The observation group was combined with hemoperfusion therapy (CVVH+HP) on the basis of the control group.Compare the two groups of laboratory indicators before and after treatment [white blood cell count (WBC), hemoglobin (Hb), urea nitrogen (BUN), blood creatinine (Scr), blood lactic acid (LAC), high sensitivity C-reactive protein (hs-CRP)], Urine volume, levels of inflammatory factors [interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor (TNF-α)], length of stay in ICU, total length of stay and mortality.Results After treatment, WBC, Hb, BUN, Scr, LAC, hs-CRP in the two groups were lower than before treatment, and urine output was higher than before treatment. All indicators were improved, and the improvement of the observation group was better than that of the control group,the difference was statistically significant (P＜0.05);After treatment, the levels of IL-6, IL-8 and TNF-α inflammatory factors in the two groups were lower than before treatment, and the observation group was lower than the control group, the difference was statistically significant (P<0.05);The length of stay in ICU, total length of hospital stay, and mortality in the observation group were lower than those in the control group,the difference was statistically significant(P<0.05).Conclusion On the basis of conventional treatment, continuous venous-venous hemofiltration combined with hemoperfusion is used to treat ICU sepsis.It can effectively improve the patient’s laboratory indicators and urine output, reduce the level of inflammatory factors, shorten the hospital stay, and reduce the mortality rate. It is worthy of clinical application.

参考文献/References:

[1]高洁,孔令博,刘斯,等.血必净注射液治疗脓毒症及多器官功能障碍综合征的前瞻性多中心临床研究[J].中华危重病急救医学,2015,27(6):465-470. [2]程宝莉.重症脓毒症流行病学调查与防御素家族基因簇拷贝数多态性的研究[D].浙江大学医学院,2009. [3]冯清,吴龙,艾宇航,等.重症监护病房脓毒症患者病原菌的流行病学特征[J].中国感染控制杂志,2018,17(9):777-782. [4]石岩.严重脓毒症发病机制新认识[J]. 中国实用外科杂志,2012,32(11):956-958. [5]霍习敏,曹利静,徐梅先,等.严重脓毒症患儿连续性静脉-静脉血液滤过疗效及治疗时间研究[J].中国小儿急救医学,2014,21(1):28-30. [6]袁超,王夜明,李鲲,等.血液灌流联合血液滤过治疗脓毒症休克临床疗效观察[J].中国临床医生杂志,2015(9):44-46. [7]严静.中国严重脓毒症/脓毒性休克治疗指南(2014):规范与实践[J].中华医学信息导报,2015,30(11):19. [8]刘辉,姚咏明.创伤脓毒症特点及救治对策[J].国际外科学杂志,2015,42(11):721-723. [9]高敏,孙宇,王宇迪,等.ICU创伤后感染患者并发脓毒症的危险因素分析[J].第三军医大学学报,2017,39(4):367-372. [10]林钦汉,张明,陈军,等.早期连续性肾脏替代治疗对严重脓毒症患者的治疗意义[J].实用心脑肺血管病杂志,2014(1):46-49. [11]冯敏,田仁富,邓明强,等.连续性静脉-静脉血液净化对脓毒症患者血流动力学、凝血功能及免疫功能的影响[J].中国医学装备,2018(3):98-102. [12]陈继红,于澈,刘健.连续性静脉-静脉血液透析滤过对多器官功能障碍综合征犬不同溶质的清除作用[J].中华肾脏病杂志,2011,27(2):124-127. [13]滕琰,丁铭,李昊,等.血液灌流治疗脓毒症时对炎症因子的影响[J].昆明医科大学学报,2016,37(5):114-117. [14]罗建宇,王晓源,吕光宇,等.血液灌流联合连续性血液滤过在脓毒症患者中的临床应用观察[J].临床肾脏病杂志,2019,19(3):157-161. [15]尤伟艳,许航.血液灌流联合连续性静脉-静脉血液滤过对严重脓毒症患者的效果分析[J].新疆医学,2019,49(3):218-220.

相似文献/References:

[1]温占兵.血管生成素-1水平变化预测脓毒症急性肺损伤的价值[J].医学信息,2018,31(13):95.[doi:10.3969/j.issn.1006-1959.2018.13.027]
　WEN Zhan-bing.The Value of Angiopoietin-1 Level Change in Predicting Acute Lung Injury in Sepsis[J].Medical Information,2018,31(13):95.[doi:10.3969/j.issn.1006-1959.2018.13.027]
[2]申 贵,彭 翔,秦光梅.抗感染督导治疗对脓毒症患者预后影响的研究[J].医学信息,2019,32(01):82.[doi:10.3969/j.issn.1006-1959.2019.01.026]
　SHEN Gui,PENG Xiang,QIN Guang-mei.Study on the Effect of Anti-infective Supervision on the Prognosis of Patients with Sepsis[J].Medical Information,2019,32(13):82.[doi:10.3969/j.issn.1006-1959.2019.01.026]
[3]张恺悦,陈幼琼.乌司他丁联合血必净对烧伤后脓毒症患者凝血功能及全身炎性反应的影响研究[J].医学信息,2019,32(04):138.[doi:10.3969/j.issn.1006-1959.2019.04.044]
　ZHANG Kai-yue,CHEN You-qiong.Effect of Ulinastatin Combined with Xuebijing on Coagulation Function and Systemic Inflammatory Response in Patients with Sepsis after Burn[J].Medical Information,2019,32(13):138.[doi:10.3969/j.issn.1006-1959.2019.04.044]
[4]张文旭,徐 绸.红细胞宽度对脓毒症患者病情诊断及预后评估的价值[J].医学信息,2022,35(14):71.[doi:10.3969/j.issn.1006-1959.2022.14.015]
　ZHANG Wen-xu,XU Chou.The Value of Red-blood-cell Distribution Width in the Diagnosis and Prognosis of Patients with Sepsis[J].Medical Information,2022,35(13):71.[doi:10.3969/j.issn.1006-1959.2022.14.015]
[5]朱思哲,叶成林.基于生物信息学分析构建免疫相关基因脓毒症预后模型[J].医学信息,2022,35(15):1.[doi:10.3969/j.issn.1006-1959.2022.15.001]
　ZHU Si-zhe,YE Cheng-lin.Identification of Immune-related Gene Prognostic Model for Sepsis Based on Bioinformatics Analysis[J].Medical Information,2022,35(13):1.[doi:10.3969/j.issn.1006-1959.2022.15.001]
[6]杨勋能.参苓白术散对脓毒症患者肠道功能的影响[J].医学信息,2019,32(16):146.[doi:10.3969/j.issn.1006-1959.2019.16.049]
　YANG Xun-neng.Effect of Shenling Baizhu Powder on Intestinal Function in Patients with Sepsis[J].Medical Information,2019,32(13):146.[doi:10.3969/j.issn.1006-1959.2019.16.049]
[7]杜金洁,胡 鹏.ESKAPE病原菌感染引起脓毒症的研究[J].医学信息,2019,32(21):33.[doi:10.3969/j.issn.1006-1959.2019.21.012]
　DU Jin-jie,HU Peng.Study on Sepsis Caused by ESKAPE Pathogen Infection[J].Medical Information,2019,32(13):33.[doi:10.3969/j.issn.1006-1959.2019.21.012]
[8]刘安平,段海真,汪 松.抗菌肽LL-37的生物学活性及其作用[J].医学信息,2019,32(24):13.[doi:10.3969/j.issn.1006-1959.2019.24.005]
　LIU An-ping,DUAN Hai-zhen,WANG Song.Biological Activity and Effect of Antibacterial Peptide LL-37[J].Medical Information,2019,32(13):13.[doi:10.3969/j.issn.1006-1959.2019.24.005]
[9]陈冀远.右美托咪啶对脓毒症急性肾损伤患者肾功能及血管紧张素Ⅱ表达的影响[J].医学信息,2020,33(01):142.[doi:10.3969/j.issn.1006-1959.2020.01.045]
　CHEN Ji-yuan.Effect of Dexmedetomidine on Renal Function and Angiotensin Ⅱ Expression in Patients with Acute Renal Injury in Sepsis[J].Medical Information,2020,33(13):142.[doi:10.3969/j.issn.1006-1959.2020.01.045]
[10]赵振宇.miR-33表达与炎症反应的关系[J].医学信息,2020,33(02):73.[doi:10.3969/j.issn.1006-1959.2020.02.020]
　ZHAO Zhen-yu.Relationship Between miR-33 Expression and Inflammatory Response[J].Medical Information,2020,33(13):73.[doi:10.3969/j.issn.1006-1959.2020.02.020]

更新日期/Last Update: 1900-01-01